Conference Coverage
Conference Coverage
Biologics may protect psoriasis patients against severe COVID-19
Preliminary evidence suggests biologics prevent the fearsome COVID-19 late cytokine storm.
Conference Coverage
Mirikizumab beats placebo, secukinumab for psoriasis
If approved, mirikizumab, which binds the p19 subunit of IL-23, would join three other IL-23 drugs already marketed in the United States for...
Conference Coverage
Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring
For patients with psoriasis concerned about their outcome if infected with COVID-19, “there is no evidence to support stopping biologics or...
Conference Coverage
Study highlights differences between White and Latino patients with psoriasis
Latinos had a higher mean percentage of body surface area involvement in the upper limbs.
Conference Coverage
Strategic approach mitigates impact of antidrug antibodies in patients with rheumatic diseases
Consider dose escalation and adding an immunomodulator to overcome the impact of antidrug antibodies in rheumatic disease patients.
Conference Coverage
Dr. Len Calabrese gives advice on vaccinating adult patients with rheumatic disease
He highlights safety protocols and advises on recommended vaccines in rheumatology practice.
Conference Coverage
Beyond PASI 100: striving for molecular clearance
A PASI 100 response, traditionally considered unreachable for most patients with severe psoriasis, soon just might not be good enough.
Conference Coverage
Cohort study finds a twofold greater psoriasis risk linked to a PCOS diagnosis
Previous retrospective analyses have suggested an increased risk of psoriasis associated with polycystic ovarian syndrome.
Conference Coverage
Biologics may delay psoriatic arthritis, study finds
A single-center study shows reduced incidence in psoriatic arthritis in psoriasis patients treated with biologics.
Conference Coverage
New developments in pustular psoriasis
Genetic factors and novel therapies could chip away at this complex condition.